Patents by Inventor Jeffrey M. Schkeryantz

Jeffrey M. Schkeryantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases
    Publication number: 20240124394
    Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 18, 2024
    Applicant: Celgene Corporation
    Inventors: Jeffrey M. Schkeryantz, Julie Selkirk, Philip Stewart Turnbull, Junko Tamiya, Patrick W. Papa, Jean-Francois Brazeau, Karin Worm
  • Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
    Patent number: 11919879
    Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: March 5, 2024
    Assignee: Celgene Corporation
    Inventors: Jeffrey M. Schkeryantz, Karin Worm, Rulin Ma, Patrick W. Papa
  • Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases
    Publication number: 20230028747
    Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
    Type: Application
    Filed: June 15, 2022
    Publication date: January 26, 2023
    Applicant: Celgene Corporation
    Inventors: Jeffrey M. Schkeryantz, Karin Worm, Rulin Ma, Patrick W. Papa
  • Glucocortiocoid-selective agents
    Patent number: 6166013
    Abstract: Compounds having Formula I ##STR1## are useful for modulating the glucocorticoid receptor in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of treating immune, autoimmune, inflammatory, adrenal imbalance, cognitive and behavioral diseases in a mammal.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: December 26, 2000
    Assignee: Abbott Laboratories
    Inventors: Michael J. Coghlan, Jay R. Luly, Jeffrey M. Schkeryantz, Alan X. Wang